CODA Biotherapeutics Announces New Preclinical Data From Epilepsy Program Showing Significant Correlation Between Gene Expression and Efficacy

Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA's engineered receptors and activator drugs in controlling seizures SOUTH SAN FRANCISCO, Calif., June 1, 2022 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a...

Click to view original post